FDA has granted accelerated approval to Tecentriq (atezolizumab) plus chemotherapy (Abraxane [nab-paclitaxel]) for the treatment of adults with unresectable locally advanced or metastatic triple-negative breast cancer in people whose tumors express PD-L1, as determined by an FDA-approved test.
Urologic oncologist Wayne Brisbane thought his patient might be a good candidate for focal therapy.
